A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: a plain language summary of the QuANTUM-First study.
Publication
, Journal Article
Erba, HP
Published in: Future Oncol
February 2025
Duke Scholars
Published In
Future Oncol
DOI
EISSN
1744-8301
Publication Date
February 2025
Volume
21
Issue
5
Start / End Page
533 / 547
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P. (2025). A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: a plain language summary of the QuANTUM-First study. Future Oncol, 21(5), 533–547. https://doi.org/10.1080/14796694.2024.2422261
Erba, Harry P. “A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: a plain language summary of the QuANTUM-First study.” Future Oncol 21, no. 5 (February 2025): 533–47. https://doi.org/10.1080/14796694.2024.2422261.
Erba, Harry P. “A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: a plain language summary of the QuANTUM-First study.” Future Oncol, vol. 21, no. 5, Feb. 2025, pp. 533–47. Pubmed, doi:10.1080/14796694.2024.2422261.
Published In
Future Oncol
DOI
EISSN
1744-8301
Publication Date
February 2025
Volume
21
Issue
5
Start / End Page
533 / 547
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis